Jonathan Corren

19.7k total citations · 7 hit papers
225 papers, 11.0k citations indexed

About

Jonathan Corren is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Jonathan Corren has authored 225 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Physiology, 102 papers in Pulmonary and Respiratory Medicine and 85 papers in Immunology and Allergy. Recurrent topics in Jonathan Corren's work include Asthma and respiratory diseases (204 papers), Allergic Rhinitis and Sensitization (82 papers) and Respiratory and Cough-Related Research (78 papers). Jonathan Corren is often cited by papers focused on Asthma and respiratory diseases (204 papers), Allergic Rhinitis and Sensitization (82 papers) and Respiratory and Cough-Related Research (78 papers). Jonathan Corren collaborates with scholars based in United States, United Kingdom and France. Jonathan Corren's co-authors include William W. Busse, Janet M. Griffiths, Niroo Gupta, Angel FowlerTaylor, Bobby Q. Lanier, Jane R. Parnes, Charles G. Irvin, Allen Adinoff, Thomas B. Casale and Giovanni Della Cioppa and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Jonathan Corren

220 papers receiving 10.6k citations

Hit Papers

Lebrikizumab Treatment in Adults with Asthma 2001 2026 2009 2017 2011 2001 2017 2016 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lebrikizumab Treatment in Adults with Asthma
    2011 1.1k citations Jonathan Corren, Nicola A. Hanania et al. New England Journal of Medicine profile →
  2. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
    2001 978 citations Jonathan Corren et al. Journal of Allergy and Clinical Immunology profile →
  3. Tezepelumab in Adults with Uncontrolled Asthma
    2017 677 citations Jonathan Corren, Jane R. Parnes et al. New England Journal of Medicine profile →
  4. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
    2016 632 citations Mario Castro, Jonathan Corren et al. profile →
  5. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
    2021 606 citations Andrew Menzies‐Gow, Jonathan Corren et al. New England Journal of Medicine profile →
  6. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
    2020 453 citations Philippe Gevaert, Theodore A. Omachi et al. Journal of Allergy and Clinical Immunology profile →
  7. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
    2023 95 citations Jonathan Corren, Andrew Menzies‐Gow et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan Corren United States 44 9.0k 5.2k 4.6k 2.6k 1.4k 225 11.0k
Barbro Dahlén Sweden 47 4.8k 0.5× 3.0k 0.6× 1.9k 0.4× 1.5k 0.6× 534 0.4× 148 7.1k
Steven W. Yancey United States 35 7.0k 0.8× 5.7k 1.1× 1.3k 0.3× 1.2k 0.5× 1.3k 0.9× 122 8.2k
Héctor Ortega United States 37 7.1k 0.8× 5.4k 1.0× 1.5k 0.3× 1.8k 0.7× 2.0k 1.4× 117 8.6k
Mina Gaga Greece 39 2.8k 0.3× 2.1k 0.4× 1.6k 0.4× 949 0.4× 316 0.2× 120 5.1k
Gregory P. Geba United States 31 3.1k 0.3× 1.6k 0.3× 1.2k 0.3× 2.2k 0.8× 783 0.6× 93 5.9k
Girolamo Pelaia Italy 41 2.6k 0.3× 2.1k 0.4× 876 0.2× 843 0.3× 666 0.5× 149 4.4k
Alessandro Vatrella Italy 41 2.4k 0.3× 1.9k 0.4× 800 0.2× 822 0.3× 620 0.4× 170 4.6k
Roland Buhl Germany 32 4.3k 0.5× 3.6k 0.7× 1.0k 0.2× 1.0k 0.4× 680 0.5× 148 5.5k
Stephen C. Lazarus United States 37 3.5k 0.4× 3.1k 0.6× 675 0.1× 1.1k 0.4× 330 0.2× 108 5.3k
Mark Hew Australia 31 2.1k 0.2× 1.9k 0.4× 468 0.1× 455 0.2× 278 0.2× 131 3.3k

Countries citing papers authored by Jonathan Corren

Since Specialization
Citations

This map shows the geographic impact of Jonathan Corren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Corren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Corren more than expected).

Fields of papers citing papers by Jonathan Corren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Corren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Corren. The network helps show where Jonathan Corren may publish in the future.

Co-authorship network of co-authors of Jonathan Corren

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Corren. A scholar is included among the top collaborators of Jonathan Corren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Corren. Jonathan Corren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McLaren, Julie, Yun Chon, Kevin Gorski, et al.. (2025). Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study. Journal of Allergy and Clinical Immunology. 155(6). 1945–1956. 8 indexed citations
2.
Corren, Jonathan, Rachel Moate, Adam Williams, et al.. (2025). FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. ERJ Open Research. 12(1). 183–2025. 1 indexed citations
3.
Bourdin, Arnaud, Jonathan Corren, Anand Shah, et al.. (2025). Dupilumab efficacy in patients with asthma and allergic bronchopulmonary aspergillosis (ABPA). OA2337–OA2337.
4.
Wipperman, Matthew F., Kaitlyn Gayvert, Amanda Atanasio, et al.. (2024). Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy. Allergy. 79(4). 894–907. 12 indexed citations
5.
Corren, Jonathan, Stanley J. Szefler, Ellen Sher, et al.. (2024). Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology In Practice. 12(5). 1215–1224.e3. 18 indexed citations
6.
Buhl, Roland, Jonathan Corren, Nicola A. Hanania, et al.. (2023). Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 79(5). 1134–1145. 19 indexed citations
7.
Laidlaw, Tanya M., Andrew Menzies‐Gow, Joseph K. Han, et al.. (2023). Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. Journal of Asthma and Allergy. Volume 16. 915–932. 30 indexed citations
8.
Pavord, Ian, Arnaud Bourdin, Alberto Papi, et al.. (2023). Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy. 78(11). 2921–2932. 6 indexed citations
9.
Szefler, Stanley J., Jonathan Corren, Jonathan I. Silverberg, et al.. (2023). Lebrikizumab Decreases Inflammatory Biomarkers in Patients with Asthma: Data from Randomized Phase 3 Trials (LAVOLTA I and II). Journal of Allergy and Clinical Immunology. 151(2). AB195–AB195. 2 indexed citations
10.
Papi, Alberto, Mario Castro, Jonathan Corren, et al.. (2021). LONG-TERM EFFECT OF DUPILUMAB ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 ASTHMA: LIBERTY ASTHMA TRAVERSE STUDY. CHEST Journal. 160(4). A1854–A1858. 1 indexed citations
11.
Corren, Jonathan, Claus Bachert, Philippe Gevaert, et al.. (2020). Omalizumab Improves Quality of Life in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma. Journal of Allergy and Clinical Immunology. 145(2). AB250–AB250. 3 indexed citations
12.
Gevaert, Philippe, Theodore A. Omachi, Jonathan Corren, et al.. (2020). Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. Journal of Allergy and Clinical Immunology. 146(3). 595–605. 453 indexed citations breakdown →
13.
Corren, Jonathan. (2019). New Targeted Therapies for Uncontrolled Asthma. The Journal of Allergy and Clinical Immunology In Practice. 7(5). 1394–1403. 62 indexed citations
14.
Corren, Jonathan, Jane R. Parnes, Liangwei Wang, et al.. (2018). Tezepelumab demonstrates clinically meaningful improvements in asthma control (ACQ-6) in patients with uncontrolled asthma: results from a phase 2b clinical trial. Journal of Allergy and Clinical Immunology. 141(2). AB80–AB80. 3 indexed citations
15.
Corren, Jonathan, Jane R. Parnes, May Mo, et al.. (2017). Tezepelumab in Adults with Uncontrolled Asthma. New England Journal of Medicine. 377(10). 936–946. 677 indexed citations breakdown →
16.
Corren, Jonathan, Steven F. Weinstein, Lindsay Janka, Christopher O’Brien, & James Zangrilli. (2014). A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal. 44(Suppl 58). 4673–4673. 13 indexed citations
17.
Corren, Jonathan, Anthony J. Frew, Michael E. Engel, et al.. (2013). Tiotropium as Add-On Therapy to ICS+LABA in Patients With Symptomatic Severe Asthma: Spirometric Assessment Over 24 Hours. CHEST Journal. 144(4). 91A–91A. 5 indexed citations
18.
Tan, Ricardo & Jonathan Corren. (2008). Mometasone furoate in the management of asthma: a review. SHILAP Revista de lepidopterología. 2 indexed citations
19.
Corren, Jonathan, et al.. (2003). COMPARISON OF ONCE‐DAILY MOMETASONE FUROATE VERSUS ONCE‐DAILY BUDESONIDE IN PATIENTS WITH MODERATE PERSISTENT ASTHMA. International Journal of Clinical Practice. 57(7). 567–572. 31 indexed citations
20.
Corren, Jonathan. (1999). Intranasal corticosteroids for allergic rhinitis : How do different agents compare? : Recent advances in the use of intranasal steroids in seasonal allergic rhinitis and sinusitis. Journal of Allergy and Clinical Immunology. 104(4). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbro Dahlén Breakdown of academic impact, for papers by Steven W. Yancey Breakdown of academic impact, for papers by Héctor Ortega Breakdown of academic impact, for papers by Mina Gaga Breakdown of academic impact, for papers by Gregory P. Geba Breakdown of academic impact, for papers by Girolamo Pelaia Breakdown of academic impact, for papers by Alessandro Vatrella Breakdown of academic impact, for papers by Roland Buhl Breakdown of academic impact, for papers by Stephen C. Lazarus Breakdown of academic impact, for papers by Mark Hew
Rankless by CCL
2026